AI
Saturday, January 23, 2016 4:18:57 PM
I do believe Dr. Raymond Birge is ALL-IN! Great find, Biopharm on Dr. Birge's Youtube statement (SEE BELOW) that perfect parallels Bavi's MOA… More later – gotta run...
= = = = = =
Rutgers' Dr. Raymond Birge, “PS: a Global Immunosuppressive Signal...”. Spoke at Peregrine's 11-2015 “Sci. Session” at SITC'15/Maryland; will be the chair in June'16 of the ICDS'16/Ireland session where Dr. Rolf Brekken (PPHM SAB) is speaking; and now also speaking in late June'16 at ICHC'16/Istanbul on, “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer”… (Rutgers Univ. http://birgelab.org “The Birge laboratory conducts basic science focussed on the eradication of cancer.”)
June19-22 2016: “15th Intl. Congress of Histochemistry & Cytochemistry - from Molecules to Diseases”, Istanbul Turkey
“The main goal of ICHC 2016 is to bring the worldwide histochemists together and provide an environment for close cooperation, exchange of information, and collaborations.”
http://www.ichc2016.com
INVITED SPEAKER – Session: “Cellular Aging & Cell Death”
Dr. Raymond Birge (Rutgers Univ. http://birgelab.org ), “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer”
= = = = = = = = = = = = = = = = = = =
3-1-14/Youtube: “Cancer Research” - Raymond Birge Laboratory, Rutgers http://birgelab.org
Dr. Birge/2:54: "The immune system is very complex and if it can recognize tumors as being foreign to the body, then it can reactivate & eliminate these tumors to treat as a chronic disease, or in some cases eliminate the tumors. One of the projects that our lab is interested in is how to reactivate the immune system toward particular cancers, and we believe that the type of cell death that cancer cells undergo will determine whether or not they'll be an immune reaction against the cancer. If cells die, through a process called apoptosis, in a certain way, they can reactivate / activate the immune system and give a durable, anti-tumor response. The problem that we're trying to understand is how the tumor cells evade the immune system and therefore block these immune-suppressing signals to reactivate the immune system against cancer..."
=======DR. RAY BIRGE (RUTGERS) & PEREGRINE:
June2-4 2016: ICDS 2016: Translational Implications in Cell Death", Cork Ireland http://tinyurl.com/h2gvyld
...Dr. Rolf Brekken (USA, UTSE, PPHM SAB): “Blockade of PS & Immune Activation in Cancer” (Chair: Dr. Raymond Birge/Rutgers – see http://tinyurl.com/oks5uo6 )
Nov4-8 2015: “(SITC) Society for Immunotherapy of Cancer 30th Annual Meeting”, Natl-Harbor MD
”The premier destination for scientific exchange, education, and networking in the Cancer Immunotherapy Field”
SITC = The Society for Immunotherapy of Cancer http://www.sitcancer.org
SITC 2015 Meeting: http://www.sitcancer.org/2015
EXHIBITOR: Peregrine Pharm. - booth #121 (directly across from #120/ASCO & BMY/124; AstraZeneca/108 & DNA/113 are close by)
...Floorplan: http://www.eventscribe.com/2015/sitc/exhibitors/index.asp
...Join Peregrine for a Scientific Session - FRI Nov6 2015 7:30-9:00pm
“The PS Signaling Pathway: A Promising
Therapeutic Target Exploited by
Tumors for Immune Evasion”
PGM:
* Raymond Birge (PhD, Rutgers) http://birgelab.org
* Douglas Graham (MD, PhD, Emory) http://choa.org/Childrens-Hospital-Services/Cancer-and-Blood-Disorders/Meet-the-Team/Physicians-and-Researchers/Douglas-Graham
* Dmitry Gabrilovich (MD, PhD, Wistar Inst.) http://www.wistar.org/our-science/scientists/dmitry-gabrilovich-md-phd
* Rolf Brekken (PhD, UTSW/Dallas) http://www.utsouthwestern.edu/labs/brekken
* Maria Karasarides (PhD, AstraZeneca - Sr. Director, ImmunoOncology, Global Medicines Dev.) http://www.linkedin.com/pub/maria-karasarides-ph-d/6/769/136
...Brochure handout (not sure if exactly it): http://www.personalizedmedonc.com/article/phosphatidylserine-an-immune-modulating-checkpoint-ushers-in-the-next-wave-of-immuno-oncology-targets/
- - - - - - - -
SITC'15 Track: “Optimizing Combination Immunotherapy”
11-7-15/Sat./12:45-2:00pm
PPHM#1: Poster P357, “Targeting of Phosphatidylserine by Monoclonal Antibodies Augments the Activity of Paclitaxel & anti-pd1/pd-L1 Therapy in the Murine Breast Model E0771”
Presenting Author: Michael Gray, PhD (Sr.Scientist, Peregrine Pharmaceuticals)
Michael Gray 1, Jian Gong 1, Van Nguyen 1, Takuya Osada 2, Zachary Hartman 2, Jeff Hutchins 1, Bruce Freimark 1, Kim (Herbert K.) Lyerly, Duke Univ.** 2
...1=Peregrine Pharmaceuticals, Tustin CA
...2=Duke University, Durham, NC
**Dr. Herbert Kim Lyerly: http://surgery.duke.edu/faculty/details/0117267 (Professor of Surgery, Assistant Professor in Immunology, Associate Professor of Pathology, Duke Univ. MC)
The other 2 Duke co-author scientists:
* Dr. Takuya Osada (MD/PhD – Duke Cancer Inst. - Hematology, Oncology, Clinical Immunology http://www.researchgate.net/profile/Takuya_Osada2 )
* Dr. Zachary Hartman (PhD) – Duke MC, Section of Applied Therapeutics http://surgery.duke.edu/faculty/details/0281172 ”My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies & dev. of vaccines to specific oncogenic targets.”
= = = = = =
Rutgers' Dr. Raymond Birge, “PS: a Global Immunosuppressive Signal...”. Spoke at Peregrine's 11-2015 “Sci. Session” at SITC'15/Maryland; will be the chair in June'16 of the ICDS'16/Ireland session where Dr. Rolf Brekken (PPHM SAB) is speaking; and now also speaking in late June'16 at ICHC'16/Istanbul on, “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer”… (Rutgers Univ. http://birgelab.org “The Birge laboratory conducts basic science focussed on the eradication of cancer.”)
June19-22 2016: “15th Intl. Congress of Histochemistry & Cytochemistry - from Molecules to Diseases”, Istanbul Turkey
“The main goal of ICHC 2016 is to bring the worldwide histochemists together and provide an environment for close cooperation, exchange of information, and collaborations.”
http://www.ichc2016.com
INVITED SPEAKER – Session: “Cellular Aging & Cell Death”
Dr. Raymond Birge (Rutgers Univ. http://birgelab.org ), “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer”
= = = = = = = = = = = = = = = = = = =
3-1-14/Youtube: “Cancer Research” - Raymond Birge Laboratory, Rutgers http://birgelab.org
Dr. Birge/2:54: "The immune system is very complex and if it can recognize tumors as being foreign to the body, then it can reactivate & eliminate these tumors to treat as a chronic disease, or in some cases eliminate the tumors. One of the projects that our lab is interested in is how to reactivate the immune system toward particular cancers, and we believe that the type of cell death that cancer cells undergo will determine whether or not they'll be an immune reaction against the cancer. If cells die, through a process called apoptosis, in a certain way, they can reactivate / activate the immune system and give a durable, anti-tumor response. The problem that we're trying to understand is how the tumor cells evade the immune system and therefore block these immune-suppressing signals to reactivate the immune system against cancer..."
=======DR. RAY BIRGE (RUTGERS) & PEREGRINE:
June2-4 2016: ICDS 2016: Translational Implications in Cell Death", Cork Ireland http://tinyurl.com/h2gvyld
...Dr. Rolf Brekken (USA, UTSE, PPHM SAB): “Blockade of PS & Immune Activation in Cancer” (Chair: Dr. Raymond Birge/Rutgers – see http://tinyurl.com/oks5uo6 )
Nov4-8 2015: “(SITC) Society for Immunotherapy of Cancer 30th Annual Meeting”, Natl-Harbor MD
”The premier destination for scientific exchange, education, and networking in the Cancer Immunotherapy Field”
SITC = The Society for Immunotherapy of Cancer http://www.sitcancer.org
SITC 2015 Meeting: http://www.sitcancer.org/2015
EXHIBITOR: Peregrine Pharm. - booth #121 (directly across from #120/ASCO & BMY/124; AstraZeneca/108 & DNA/113 are close by)
...Floorplan: http://www.eventscribe.com/2015/sitc/exhibitors/index.asp
...Join Peregrine for a Scientific Session - FRI Nov6 2015 7:30-9:00pm
“The PS Signaling Pathway: A Promising
Therapeutic Target Exploited by
Tumors for Immune Evasion”
PGM:
* Raymond Birge (PhD, Rutgers) http://birgelab.org
* Douglas Graham (MD, PhD, Emory) http://choa.org/Childrens-Hospital-Services/Cancer-and-Blood-Disorders/Meet-the-Team/Physicians-and-Researchers/Douglas-Graham
* Dmitry Gabrilovich (MD, PhD, Wistar Inst.) http://www.wistar.org/our-science/scientists/dmitry-gabrilovich-md-phd
* Rolf Brekken (PhD, UTSW/Dallas) http://www.utsouthwestern.edu/labs/brekken
* Maria Karasarides (PhD, AstraZeneca - Sr. Director, ImmunoOncology, Global Medicines Dev.) http://www.linkedin.com/pub/maria-karasarides-ph-d/6/769/136
...Brochure handout (not sure if exactly it): http://www.personalizedmedonc.com/article/phosphatidylserine-an-immune-modulating-checkpoint-ushers-in-the-next-wave-of-immuno-oncology-targets/
- - - - - - - -
SITC'15 Track: “Optimizing Combination Immunotherapy”
11-7-15/Sat./12:45-2:00pm
PPHM#1: Poster P357, “Targeting of Phosphatidylserine by Monoclonal Antibodies Augments the Activity of Paclitaxel & anti-pd1/pd-L1 Therapy in the Murine Breast Model E0771”
Presenting Author: Michael Gray, PhD (Sr.Scientist, Peregrine Pharmaceuticals)
Michael Gray 1, Jian Gong 1, Van Nguyen 1, Takuya Osada 2, Zachary Hartman 2, Jeff Hutchins 1, Bruce Freimark 1, Kim (Herbert K.) Lyerly, Duke Univ.** 2
...1=Peregrine Pharmaceuticals, Tustin CA
...2=Duke University, Durham, NC
**Dr. Herbert Kim Lyerly: http://surgery.duke.edu/faculty/details/0117267 (Professor of Surgery, Assistant Professor in Immunology, Associate Professor of Pathology, Duke Univ. MC)
The other 2 Duke co-author scientists:
* Dr. Takuya Osada (MD/PhD – Duke Cancer Inst. - Hematology, Oncology, Clinical Immunology http://www.researchgate.net/profile/Takuya_Osada2 )
* Dr. Zachary Hartman (PhD) – Duke MC, Section of Applied Therapeutics http://surgery.duke.edu/faculty/details/0281172 ”My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies & dev. of vaccines to specific oncogenic targets.”
